Related Experiment Video

Updated: May 9, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

15.4K

Cost-effectiveness analysis of implementing 20-valent pneumococcal conjugate vaccine into the Romanian pediatric

Alin Preda1, An Ta2, Elizabeth Vinand2

  • 1Pfizer Romania, Bucharest, Romania.

Journal of Medical Economics
|April 30, 2025
PubMed

Insights

Switching to the 20-valent pneumococcal conjugate vaccine (PCV20) in Romania

Area of Science:

  • Public Health
  • Vaccinology
  • Health Economics

Background:

  • Romania faces a significant burden from pneumococcal disease despite current pediatric vaccination programs.
  • Higher-valent pneumococcal conjugate vaccines (PCVs) like PCV20 offer broader serotype coverage than existing vaccines (PCV13, PCV15).

Purpose of the Study:

  • To evaluate the cost-effectiveness of introducing the 20-valent pneumococcal conjugate vaccine (PCV20) into Romania's national immunization program.
  • To compare PCV20 against the current 13-valent PCV (PCV13) and a potential 15-valent PCV (PCV15) from a societal perspective.

Main Methods:

  • A population-based, multi-cohort Markov model was used to simulate the impact over 10 years in children under 2 years old.
  • The analysis adopted a Romanian societal perspective, including direct and indirect costs.
  • Sensitivity and scenario analyses were performed to ensure model robustness.

Main Results:

  • PCV20 demonstrated dominance over both PCV13 and PCV15, being more effective and less costly.
  • The model predicted cost savings of over 79 million RON versus PCV13 and over 206 million RON versus PCV15.
  • A reduction of 246,245 cases (vs. PCV13) and 223,914 cases (vs. PCV15) of pneumococcal disease was projected.

Conclusions:

  • Implementing PCV20 in Romania's pediatric national immunization program is a cost-effective strategy.
  • PCV20 is projected to significantly reduce the burden of pneumococcal disease from a societal viewpoint over a 10-year period.
Abstract

Keywords:
I15I18PCV13PCV15PCV20Romaniacost-effectivenessnational immunization programpediatricpneumococcal conjugate vaccinationvaccination

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.0K
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.7K

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...